
Survodutide achieved up to 13.1% weight loss vs 3.1% with placebo at 76 weeks in adults with obesity and T2D in the phase 3 SYNCHRONIZE-2 trial.
The American Journal of Managed Care
about 24 years ago
A Word From the New Editorsabout 24 years ago
The Costs of Medical Research: Still Not a Simple Story to Tell





